فرع الادوية
Medical Terminology \ Grade 1
Code: TERM107 Credits: 2
1. Medical Terminology: Introduction
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM1.1 |
Distinguish among the four elements of medical TERMs. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM1.2 |
State the rules for determining singular and plural endings. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM1.3 |
Recognize the importance of proper spelling and pronunciation of medical TERMs. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
2. Medical Discoveries: Penicillin
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM2.2 |
Explain the impact of the discovery of penicillin on the treatment of bacterial infections. |
K,A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM2.3 |
Summarize the process of penicillin's development from discovery to clinical use. |
K,A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
3. Medical Terms – Body Systems
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM3.1 |
a. List the structural levels of the body.
b. Identify examples of organs within the human body. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM3.2 |
Use anatomical directional TERMs to describe the relative location of body parts. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM3.3 |
Use word roots to understand the meaning of medical TERMs related to body systems. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
4. Medical Discoveries – Heart Transplant
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM4.1 |
Recall the year of the first successful human heart transplant. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM4.2 |
Explain the significance of the first heart transplant in the history of medicine. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
5. Case Study – OA Medical Terms
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM5.1 |
Recall common synonyms for osteoarthritis, such as degenerative joint disease. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM5.2 |
Remember the meaning of the suffix "-itis" in the context of osteoarthritis. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM5.3 |
Recall the meaning of the prefix "osteo-" and "arthr-". |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
6. Skeletal System
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM6.1 |
List the two main divisions of the skeleton. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM6.2 |
Explain the meaning of medical TERMs related to the skeletal system. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM6.3 |
Relate the roots to their corresponding anatomical structures. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
7.Medical Discoveries – DNA
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM7.1 |
Recall the year in which the double helix structure of DNA was described. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM7.2 |
Explain the significance of the discovery of DNA's structure for modern genetics. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM7.3 |
Compare and contrast the components of DNA and RNA. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
8. Case Study – DM
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM8.1 |
Define Type 2 Diabetes Mellitus. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM8.2 |
Explain the physiological effects of diabetes on the body. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM8.3 |
Calculate a patient's BMI given their weight and height. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
9. Medical Discoveries – IVF
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM9.1 |
a. Define in vitro Fertilization (IVF)
b. Summarize the IVF procedure |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM9.2 |
Explain the purpose of IVF. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
10. Medical Terms – CV System
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM10.1 |
a. Define the TERMs "Cardio-" and "Vascular"
b. Name the three types of blood vessels |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM10.2 |
Describe the function of the endocardium, myocardium, and pericardium. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
11. Medical Discoveries – HIV
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM11.1 |
State the year in which the virus responsible for AIDS was identified. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM11.2 |
Describe the basic characteristics of HIV. |
K, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
12. Medical TERMs – GIT
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM12.1 |
a. List the main parts of the GIT.
b. Identify the accessory organs of the digestive system. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM12.2 |
Describe the overall function of the digestive system. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
13. Case Study – Peptic Ulcer
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM13.1 |
a. Identify the locations of gastric and duodenal ulcers.
b. List common symptoms of peptic ulcers. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM13.2 |
Describe the role of H. pylori in the pathology of peptic ulcers. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
14. Case Study – Thyroid
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM14.1 |
Identify signs of hyperthyroidism from a physical examination. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM14.2 |
Describe the presentation of hyperthyroidism caused by Graves' disease. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
15. Medical TERMs – Skin
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM15.1 |
List the accessory structures of the skin. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM15.2 |
Describe the basic structure and components of the skin. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM15.3 |
Identify examples of skin lesions. |
K |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
16. Case Study – Eye
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM16.1 |
Identify the symptoms reported by the patient in the case study. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM16.2 |
Use appropriate medical terminology to describe the patient's condition in the case study. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
17. Case Study – Renal Stone
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| TERM17.1 |
Recall common locations where renal stones can be found (e.g., kidney, ureter, bladder). |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM17.2 |
Identify different types of renal stones (e.g., calcium oxalate, uric acid, struvite). |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
| TERM17.3 |
Use medical terminology to accurately document a patient's symptoms related to renal stones. |
K, S, A |
Large group lectures: interactive and case studies |
Multiple choice questions, reports and posters |
Pharmacology - Grade 3
Code: PHAR 302 Credits: 8
Introduction to pharmacology
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR1.1 |
Understand general terms used in pharmacology, expiry date, counterfeit medicine, .. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR1.2 |
Describe cellular targets for drug action and outline general requirements for studying pharmacology |
K |
Large group lecture |
MCQ & short answer questions |
Drug administration
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR2.1 |
Define pharmacokinetics and explain major divisions |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR2.2 |
Discuss routes of drug administration and describe major characteristics of each route of drug administration |
K |
Large group lecture |
MCQ & short answer questions |
Drug absorption
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR3.1 |
Discuss mechanisms of drug absorption of drugs from the GI tract |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR3.2 |
Determine factors influencing drug absorption. Define the term “bioavailability” of drugs and factors influencing it. |
K |
Large group lecture |
MCQ & short answer questions |
Drug distribution
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR4.1 |
Define factors affecting drug distribution: including blood flow, capillary permeability, plasma protein binding, and chemical properties of the drug, such as hydrophobicity or hydrophilicity. Volume of distribution as a measure of drug distribution. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR4.2 |
Clinical significance of drug distribution: Impacts on drug efficacy, duration of action, and dosing. Competition and displacement from protein binding sites as a source of significant drug interactions, such as increased warfarin effect when displaced from albumin by most NSAIDs. |
K |
Large group lecture |
MCQ & short answer questions |
Metabolism and elimination
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR5.1 |
Understand the processes of drug metabolism and elimination, explaining the role of the liver and kidney in drug clearance, including phase I and phase II metabolic reactions, enzyme induction/inhibition, and renal role in drug clearance. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR5.2 |
Apply pharmacokinetic principles to drug clearance; differentiate between first-order and zero-order kinetics, describe factors affecting drug elimination, and understand concepts such as half-life, steady-state concentration, and creatinine clearance in clinical settings. |
K |
Large group lecture |
MCQ & short answer questions |
Pharmacodynamics
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR6.1 |
A. Understand the mechanisms of drug action
B. Explain the different types of drug targets and describe how drugs interact with these targets to produce biological effects.
C. Compare and contrast the four major types of receptors (ligand-gated ion channels, G-protein-coupled receptors, enzyme-linked receptors, and intracellular receptors) in terms of structure, function, and response duration.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR6.2 |
Analyze drug-receptor interactions and their clinical implications:
A. Differentiate between agonists (full, partial, inverse) and antagonists (competitive, irreversible, functional, chemical) and their effects on receptor activity.
B. Evaluate the concepts of potency, efficacy, therapeutic index, and receptor desensitization, and apply these principles to predict drug behavior in therapeutic or toxic contexts.
|
K |
Large group lecture |
MCQ & short answer questions |
Introduction for Autonomic Nervous System
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR7.1 |
A. Describe the anatomical divisions of the nervous system, including CNS and PNS.
B. Explain their primary components (brain, spinal cord, and peripheral nerves).
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR7.2 |
A. Understand the role and significance of the autonomic nervous system (ANS) within the nervous system.
B. Identify its key functions in regulating involuntary physiological processes.
|
K |
Large group lecture |
MCQ & short answer questions |
Adrenergic Pharmacology Part 1
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR8.1 |
A. Understand the mechanism of action of adrenergic drugs.
B. Explain how adrenergic drugs interact with alpha and beta adrenergic receptors to either stimulate or block their activity.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR8.2 |
Identify the therapeutic applications and side effects of adrenergic medications; recognizing the therapeutic uses of common adrenergic drugs (e.g., asthma, hypertension, heart failure, anaphylaxis, …), as well as their potential side effects (e.g., tachycardia, hypertension, arrhythmias, …).
|
K |
Large group lecture |
MCQ & short answer questions |
Adrenergic Pharmacology Part 2
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR9.1 |
Understand the mechanism of action of adrenergic agonists and antagonists apart from those acting directly on adrenergic receptors (e.g., centrally acting medications, MAO and COMT inhibitors, adrenergic neuron blockers, uptake inhibitors, ganglion blockers, …).
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR9.2 |
Identify the therapeutic applications and side effects of adrenergic medications apart from those acting directly on adrenergic receptors as shown in PHAR 9.1.
|
K |
Large group lecture |
MCQ & short answer questions |
Cholinergic Agonists
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR10.1 |
Understand the mechanism of action and therapeutic applications of cholinergic agonists: explain how they interact with muscarinic and nicotinic receptors, and describe clinical uses in glaucoma, myasthenia gravis, and Alzheimer’s disease.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR10.2 |
Discuss the physiological effects and side effects of cholinergic agonists on the ANS, such as bradycardia, increased glandular secretions, and smooth muscle contraction, and explain the adverse effects.
|
K |
Large group lecture |
MCQ & short answer questions |
Cholinergic Antagonists
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR11.1 |
Understand the mechanisms of action and therapeutic uses of cholinergic antagonists: describe how they block muscarinic and nicotinic receptors, and outline clinical applications in conditions like motion sickness, intestinal and ureteral colic, overactive bladder, and Parkinson's disease.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR11.2 |
Explain the physiological outcomes of cholinergic antagonism, including tachycardia, reduced glandular secretions, and smooth muscle relaxation, and discuss how these effects are used in therapy or contribute to side effects.
|
K |
Large group lecture |
MCQ & short answer questions |
Neuromuscular-blocking Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR12.1 |
Classify neuromuscular-blocking drugs into depolarizing and non-depolarizing agents, and explain their mechanisms of action.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR12.2 |
Describe the clinical applications and side effects of neuromuscular blockers in anesthesia, surgery, and critical care, as well as their reversal strategies.
|
K |
Large group lecture |
MCQ & short answer questions |
Autacoids Part 1
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR13.1 |
Discuss the types and physiological roles of the autacoids (e.g., histamine, serotonin, eicosanoids, bradykinin, …) in the body.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR13.2 |
Explain the clinical relevance of autacoids, including their role in inflammation, allergic reactions, and therapeutic applications in asthma, peptic ulcer, inflammatory diseases, and analgesia.
|
K |
Large group lecture |
MCQ & short answer questions |
Autacoids Part 2
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR14.1 |
Describe the biosynthesis, metabolism, and mechanism of action of key autacoids.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR14.2 |
Discuss the therapeutic applications of autacoid-modulating drugs, such as NSAIDs, antihistamines, and serotonin antagonists, in managing pain, inflammation, migraine, and cardiovascular conditions.
|
K |
Large group lecture |
MCQ & short answer questions |
Respiratory Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR15.1 |
A. Understand the pharmacology and mechanism of action of respiratory drugs.
B. Explain how bronchodilators (β₂-agonists, anticholinergics), corticosteroids, leukotriene inhibitors, and mucolytics work in treating asthma and COPD.
Clinical Benefit: Helps in selecting the right drug for optimal airway management, improving patient outcomes.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR15.2 |
A. Demonstrate safe and effective use of respiratory medications.
B. Identify appropriate indications, dosages, and potential side effects of common respiratory drugs.
C. Recognize adverse effects such as tachycardia with β₂-agonists or oral thrush with inhaled corticosteroids and implement preventive measures.
Clinical Benefit: Enhances patient adherence, minimizes side effects, and improves disease control.
|
K |
Large group lecture |
MCQ & short answer questions |
Antihypertensive Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR16.1 |
Classify antihypertensive drugs based on their mechanisms of action, including diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, and ARBs. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR16.2 |
Explain the clinical applications of antihypertensive drugs, their benefits in managing hypertension, and their role in preventing cardiovascular complications such as stroke and heart failure. |
K |
Large group lecture |
MCQ & short answer questions |
Anti-anginal Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR17.1 |
Classify anti-anginal drugs into nitrates, beta-blockers, and calcium channel blockers, and explain their mechanisms of action in relieving myocardial ischemia. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR17.2 |
Describe the clinical applications of anti-anginal drugs in managing stable, unstable, and variant angina, along with their benefits in improving exercise tolerance and reducing cardiac workload. |
K |
Large group lecture |
MCQ & short answer questions |
Antiarrhythmic Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR18.1 |
Classify antiarrhythmic drugs based on the Vaughan Williams classification and explain their mechanisms of action in regulating cardiac rhythm. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR18.2 |
Describe the clinical applications of antiarrhythmic drugs in managing conditions like atrial fibrillation, ventricular tachycardia, and other arrhythmias, along with their potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Heart Failure
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR19.1 |
Explain the pathophysiology of heart failure, including its types (systolic vs. diastolic) and compensatory mechanisms. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR19.2 |
Describe the clinical use of drugs such as ACE inhibitors, beta-blockers, diuretics, and inotropes in managing heart failure and improving patient outcomes. |
K |
Large group lecture |
MCQ & short answer questions |
Anticoagulants
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR20.1 |
Classify anticoagulants into heparins, vitamin K antagonists, and direct oral anticoagulants (DOACs), and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR20.2 |
Describe the clinical applications of anticoagulants in preventing and treating thromboembolic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation, along with their monitoring and potential complications. |
K |
Large group lecture |
MCQ & short answer questions |
Diuretics
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR21.1 |
Classify diuretics based on their site of action in the nephron, including loop diuretics, thiazides, potassium-sparing diuretics, and osmotic diuretics, and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR21.2 |
Describe the clinical applications of diuretics in managing conditions such as hypertension, heart failure, and edema, along with their potential side effects and electrolyte imbalances. |
K |
Large group lecture |
MCQ & short answer questions |
Drugs for Dyslipidemia
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR22.1 |
Classify the main classes of drugs used to treat dyslipidemia, including statins, fibrates, bile acid sequestrants, niacin, and PCSK9 inhibitors, and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR22.2 |
Describe the clinical applications of dyslipidemia drugs in managing conditions such as hypercholesterolemia, hypertriglyceridemia, and their role in preventing cardiovascular diseases, including atherosclerosis and stroke. |
K |
Large group lecture |
MCQ & short answer questions |
Anemia
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR23.1 |
Classify the types of anemia (e.g., iron deficiency anemia, megaloblastic anemia, hemolytic anemia) and explain their underlying pathophysiology. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR23.2 |
Describe the clinical use of pharmacological agents in the treatment of anemia, including iron supplements, vitamin B12 and folic acid, erythropoiesis-stimulating agents (ESAs), and their potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Introduction to CNS Pharmacology
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR24.1 |
Explain the basic principles of pharmacokinetics and pharmacodynamics as they relate to drugs acting on the central nervous system (CNS). |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR24.2 |
Classify major classes of CNS drugs (e.g., analgesics, anesthetics, antipsychotics, antidepressants, anticonvulsants) and describe their mechanisms of action, therapeutic uses, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Drugs Used to Treat Headache Disorders
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR25.1 |
Classify the drugs used to treat different types of headaches, including acute and preventive treatments for migraines, tension-type headaches, and cluster headaches, and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR25.2 |
Describe the clinical applications and potential side effects of common headache treatments. |
K |
Large group lecture |
MCQ & short answer questions |
Alzheimer Disease and Multiple Sclerosis
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR26.1 |
Explain the pathophysiology of Alzheimer's disease and multiple sclerosis, focusing on the underlying mechanisms such as amyloid plaques and neurofibrillary tangles in Alzheimer's, and demyelination in multiple sclerosis. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR26.2 |
Describe the pharmacological treatments for Alzheimer's disease (e.g., cholinesterase inhibitors, NMDA antagonists) and multiple sclerosis (e.g., disease-modifying therapies, corticosteroids), including their mechanisms of action, clinical applications, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Drugs of Parkinson Disease
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR27.1 |
Classify the main pharmacological treatments for Parkinson’s disease, including dopaminergic agents (e.g., levodopa, dopamine agonists), MAO-B inhibitors, and COMT inhibitors, and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR27.2 |
Describe the clinical applications, benefits, and potential side effects of Parkinson’s disease medications, focusing on improving motor symptoms and managing side effects such as dyskinesia and motor fluctuations. |
K |
Large group lecture |
MCQ & short answer questions |
Anti-Depressant Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR28.1 |
Classify the major classes of antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR28.2 |
Describe the clinical applications, benefits, and potential side effects of antidepressant drugs in managing depression, anxiety disorders, and other mood disorders. |
K |
Large group lecture |
MCQ & short answer questions |
Anti-Psychotic Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR29.1 |
Classify antipsychotic drugs into first-generation (typical) and second-generation (atypical) antipsychotics, and explain their mechanisms of action, particularly their effects on dopamine and serotonin receptors. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR29.2 |
Describe the clinical applications, benefits, and potential side effects of antipsychotic drugs in managing conditions such as schizophrenia, bipolar disorder, and acute psychotic episodes, along with their long-term use considerations. |
K |
Large group lecture |
MCQ & short answer questions |
Anti-Epileptic Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR30.1 |
Understand the mechanisms of action of anti-epileptic drugs (AEDs), including sodium channel blockers, GABA enhancers, and calcium channel modulators.
Clinical Benefit: Helps in selecting the most appropriate drug for different seizure types and minimizing side effects. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR30.2 |
Demonstrate knowledge of AED selection and management in patients: Identify first-line and alternative AEDs for focal and generalized seizures. Understand dose adjustments, side effect management, and drug interactions.
Clinical Benefit: Enhances patient safety, improves seizure control, and reduces adverse drug reactions. |
K |
Large group lecture |
MCQ & short answer questions |
Anxiolytic and Hypnotic Drugs Part 1
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR31.1 |
Classify anxiolytic and hypnotic drugs, including benzodiazepines, non-benzodiazepine sedatives, and barbiturates, and explain their mechanisms of action on GABA receptors in the central nervous system. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR31.2 |
Describe the clinical applications of anxiolytic and hypnotic drugs in treating anxiety disorders, insomnia, and acute stress, including their onset of action, duration, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Anxiolytic and Hypnotic Drugs Part 2
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR32.1 |
Explain the pharmacokinetics and adverse effects of anxiolytic and hypnotic drugs, focusing on tolerance, dependence, and withdrawal symptoms associated with long-term use. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR32.2 |
Discuss alternative therapies to traditional anxiolytic and hypnotic drugs, including selective serotonin reuptake inhibitors (SSRIs) for anxiety and melatonin agonists for insomnia, and their clinical applications. |
K |
Large group lecture |
MCQ & short answer questions |
Epilepsy
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR33.1 |
Classify the different types of seizures (e.g., generalized, focal) and explain the underlying pathophysiology of epilepsy, focusing on the role of abnormal neuronal excitability. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR33.2 |
Describe the pharmacological treatments for epilepsy, including antiepileptic drugs (AEDs) such as sodium channel blockers, GABA enhancers, and glutamate inhibitors, along with their mechanisms of action, clinical uses, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
General Anesthetics
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR34.1 |
Understand the mechanisms of general anesthetics: Act on GABA and NMDA receptors to induce anesthesia.
Clinical Benefit: Helps in selecting appropriate anesthetic agents for patient safety. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR34.2 |
Demonstrate safe use of general anesthetics: Recognize indications, contraindications, and complications (e.g., hypotension, malignant hyperthermia).
Clinical Benefit: Enhances perioperative safety and reduces adverse effects. |
K |
Large group lecture |
MCQ & short answer questions |
Local Anesthetic Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR35.1 |
A. Understand the mechanism of action and classification of local anesthetics.
B. Explain how local anesthetics block sodium channels to prevent nerve conduction.
C. Differentiate between amide (e.g., lidocaine, bupivacaine) and ester (e.g., procaine, tetracaine) anesthetics.
Clinical Benefit: Helps in selecting the appropriate anesthetic for different procedures, ensuring effective pain control.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR35.2 |
A. Recognize and manage local anesthetic toxicity.
B. Identify signs of Local Anesthetic Systemic Toxicity (LAST) (e.g., CNS symptoms, cardiac toxicity).
C. Understand management strategies, including lipid emulsion therapy for severe toxicity.
Clinical Benefit: Enhances patient safety by preventing and managing adverse effects effectively.
|
K |
Large group lecture |
MCQ & short answer questions |
Opioids
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR36.1 |
Classify opioid drugs based on their receptor binding properties (e.g., mu, kappa, delta receptors) and explain their mechanisms of action in pain modulation and their effects on the central nervous system. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR36.2 |
Describe the clinical applications of opioids in managing acute and chronic pain, including their potential side effects such as tolerance, dependence, and respiratory depression, and the strategies to mitigate these risks. |
K |
Large group lecture |
MCQ & short answer questions |
Antiemetics
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR37.1 |
Classify antiemetic drugs based on their mechanisms of action, including dopamine antagonists, serotonin (5-HT3) antagonists, antihistamines, and corticosteroids, and explain how they prevent nausea and vomiting. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR37.2 |
Describe the clinical applications of antiemetic drugs in managing nausea and vomiting associated with conditions such as chemotherapy, motion sickness, and post-operative recovery. |
K |
Large group lecture |
MCQ & short answer questions |
Peptic Ulcer
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR38.1 |
Explain the pathophysiology of peptic ulcers, including the role of Helicobacter pylori infection, gastric acid hypersecretion, and mucosal protection in ulcer formation. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR38.2 |
Describe the pharmacological treatments for peptic ulcers, including proton pump inhibitors (PPIs), H2 receptor antagonists, antibiotics (for H. pylori), and antacids, and discuss their mechanisms of action, clinical applications, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Constipation
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR39.1 |
Classify the different causes of constipation, including primary (functional) and secondary (due to underlying diseases or medications), and explain the pathophysiology of each type. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR39.2 |
Describe the pharmacological treatments for constipation, including bulk-forming agents, stool softeners, osmotic laxatives, stimulant laxatives, and prokinetic drugs, and discuss their mechanisms of action, clinical applications, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Diarrhea
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR40.1 |
Classify the different types of diarrhea, including acute, chronic, and infectious diarrhea, and explain their underlying causes and pathophysiology. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR40.2 |
Describe the pharmacological treatments for diarrhea, including antimotility agents (e.g., loperamide), adsorbents, antibiotics (for infectious causes), and oral rehydration solutions (ORS), and discuss their mechanisms of action, clinical applications, and potential side effects. |
K |
Large group lecture |
MCQ & short answer questions |
Pharmacology - Osteoporosis
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR41.1 |
Explain the pathophysiology of osteoporosis, including the role of bone resorption and formation, and the impact of hormonal changes (e.g., estrogen deficiency) on bone density. |
K/S/A |
Large group lecture |
MCQ & short answer questions |
| PHAR41.2 |
A. Describe the pharmacological treatments for osteoporosis.
B. Discuss their mechanisms of action, clinical applications, and potential side effects. |
K/S/A |
Large group lecture |
MCQ & short answer questions |
Anti-rheumatic and DMARD
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR42.1 |
A. Classify anti-rheumatic drugs into non-biologic DMARDs (e.g., methotrexate, sulfasalazine) and biologic DMARDs (e.g., TNF inhibitors, IL-6 inhibitors).
B. Explain their mechanisms of action in modulating the immune system to reduce inflammation in conditions like rheumatoid arthritis.
|
K/S/A |
Large group lecture |
MCQ & short answer questions |
| PHAR42.2 |
A. Describe the clinical applications of DMARDs in managing autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and lupus.
B. Discuss their potential side effects, including immunosuppression and increased infection risk.
|
K/S/A |
Large group lecture |
MCQ & short answer questions |
Pharmacology - Gout
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR43.1 |
Explain the pathophysiology of gout, focusing on the accumulation of uric acid crystals in joints and the role of hyperuricemia in the development of acute gout attacks. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR43.2 |
A. Describe the pharmacological treatments for gout, including drugs that reduce uric acid production (e.g., allopurinol, febuxostat), drugs that increase uric acid excretion (e.g., probenecid), and anti-inflammatory agents (e.g., colchicine, NSAIDs).
B. Discuss their mechanisms of action, clinical applications, and potential side effects.
|
K |
Large group lecture |
MCQ & short answer questions |
Pharmacology - Obesity
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR44.1 |
Explain the pathophysiology of obesity, including the role of energy balance, genetic factors, and hormonal regulation (e.g., leptin, ghrelin) in the development of obesity. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR44.2 |
A. Describe the pharmacological treatments for obesity, including appetite suppressants (e.g., phentermine, liraglutide), lipase inhibitors (e.g., orlistat), and other weight loss agents (e.g., GLP-1 receptor agonists).
B. Discuss their mechanisms of action, clinical applications, and potential side effects.
|
K |
Large group lecture |
MCQ & short answer questions |
Non-Steroidal Anti-Inflammatory Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR45.1 |
Classify NSAIDs based on their mechanisms of action, including COX-1 and COX-2 inhibition, and explain how they reduce inflammation, pain, and fever. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR45.2 |
Describe the clinical applications of NSAIDs in managing conditions such as arthritis, pain, and dysmenorrhea, and discuss their potential side effects, including gastrointestinal bleeding, renal impairment, and cardiovascular risks. |
K |
Large group lecture |
MCQ & short answer questions |
Introduction to Antimicrobial Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR46.1 |
Classify antimicrobial drugs into their major classes, including antibiotics, antifungals, antivirals, and antiprotozoals, and explain their mechanisms of action in inhibiting microbial growth or replication. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR46.2 |
Describe the clinical applications of antimicrobial drugs in treating bacterial, viral, fungal, and parasitic infections, and discuss their spectrum of activity, potential side effects, and the importance of antibiotic stewardship to prevent resistance. |
K |
Large group lecture |
MCQ & short answer questions |
Beta-lactam Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR47.1 |
Classify beta-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems, and explain their mechanisms of action in inhibiting bacterial cell wall synthesis. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR47.2 |
Describe the clinical applications of beta-lactam drugs in treating a variety of bacterial infections, including respiratory, urinary, and skin infections, and discuss their potential side effects, such as allergic reactions and the development of resistance. |
K |
Large group lecture |
MCQ & short answer questions |
Inhibitors of Protein Synthesis
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR48.1 |
Classify the major classes of protein synthesis inhibitors, including macrolides, tetracyclines, aminoglycosides, and chloramphenicol, and explain their mechanisms of action in inhibiting bacterial ribosomal function and protein production. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR48.2 |
Describe the clinical applications of protein synthesis inhibitors in treating bacterial infections, their spectrum of activity, and their potential side effects, such as gastrointestinal disturbances, ototoxicity, and nephrotoxicity. |
K |
Large group lecture |
MCQ & short answer questions |
Quinolones
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR49.1 |
Explain the mechanism of action of quinolones, focusing on their inhibition of bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication and transcription. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR49.2 |
Describe the clinical applications of quinolones in treating a variety of bacterial infections, including urinary tract infections, respiratory infections, and gastrointestinal infections, as well as their potential side effects such as tendonitis, QT prolongation, and gastrointestinal disturbances. |
K |
Large group lecture |
MCQ & short answer questions |
Anti-mycobacterial Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR50.1 |
Classify the main anti-mycobacterial drugs used in the treatment of tuberculosis (TB), including first-line drugs (e.g., isoniazid, rifampin, pyrazinamide, ethambutol) and second-line drugs (e.g., fluoroquinolones, aminoglycosides), and explain their mechanisms of action. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR50.2 |
A. Describe the clinical applications of anti-mycobacterial drugs in treating tuberculosis, including the importance of combination therapy for drug-resistant TB.
B. Discuss their potential side effects, such as hepatotoxicity, neuropathy, and visual disturbances. |
K |
Large group lecture |
MCQ & short answer questions |
Antiviral Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR51.1 |
Classify antiviral drugs based on their mechanisms of action, including inhibitors of viral entry, replication, and release, such as nucleoside analogs, protease inhibitors, and neuraminidase inhibitors. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR51.2 |
Describe the clinical applications of antiviral drugs in treating viral infections like influenza, HIV, herpes simplex virus (HSV), and hepatitis, and discuss their potential side effects and the challenges of antiviral resistance. |
K |
Large group lecture |
MCQ & short answer questions |
Antifungal Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR52.1 |
Classify antifungal drugs into major classes, including azoles, polyenes, echinocandins, and allylamines, and explain their mechanisms of action in inhibiting fungal cell membrane synthesis or cell wall formation. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR52.2 |
Describe the clinical applications of antifungal drugs in treating common fungal infections, such as candidiasis, aspergillosis, and dermatophytosis, and discuss their potential side effects, such as hepatotoxicity, nephrotoxicity, and drug interactions. |
K |
Large group lecture |
MCQ & short answer questions |
Antiprotozoal Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR53.1 |
Classify antiprotozoal drugs into their major classes, including antimalarials (e.g., chloroquine, artemisinin), antileishmanial (e.g., miltefosine), and antiamoebic agents (e.g., metronidazole), and explain their mechanisms of action in inhibiting protozoan growth and replication. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR53.2 |
Describe the clinical applications of antiprotozoal drugs in treating diseases caused by protozoan infections, such as malaria, leishmaniasis, and giardiasis, and discuss their potential side effects, such as gastrointestinal disturbances, neurotoxicity, and drug resistance. |
K |
Large group lecture |
MCQ & short answer questions |
Anthelmintic Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR54.1 |
A. Understand the Mechanism of Action and Classification of Anthelmintic Drugs.
B. Learn how different classes of anthelmintic drugs work, their targets, and their pharmacological effects on parasitic worms.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR54.2 |
A. Apply Knowledge of Anthelmintic Drugs in Clinical Practice (Clinical Benefit).
B. Identify appropriate anthelmintic treatment for specific helminth infections, ensuring effective parasite elimination while minimizing side effects and drug resistance.
|
K |
Large group lecture |
MCQ & short answer questions |
Antidiabetic Drugs
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR54.1 |
A. Understand the Classification and Mechanisms of Action of Antidiabetic Drugs.
B. Learn how different classes of antidiabetic drugs work, their pharmacological effects, and their role in diabetes management.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR54.2 |
Apply Evidence-Based Drug Selection in Clinical Practice (Clinical Benefit). Identify and prescribe appropriate antidiabetic therapy based on patient-specific factors such as blood glucose levels, comorbidities, risk of hypoglycemia, and cardiovascular or renal benefits. |
K |
Large group lecture |
MCQ & short answer questions |
Thyroid Hormones
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR55.1 |
A. Understand the Mechanism of Action, Pharmacokinetics, and Functions of Thyroid Hormone Drugs.
B. Learn how thyroid hormone drugs (e.g., levothyroxine, liothyronine) work and their metabolism.
|
K |
Large group lecture |
MCQ & short answer questions |
| PHAR55.2 |
Apply Thyroid Hormone Therapy in Clinical Practice (Clinical Benefit). Select and adjust appropriate thyroid hormone replacement therapy based on patient-specific factors (e.g., TSH levels, comorbidities, age) to ensure effective treatment of hypothyroidism and other thyroid disorders. |
K |
Large group lecture |
MCQ & short answer questions |
Adrenocorticosteroids
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR56.1 |
Understand the Classification, Mechanism of Action, and Physiological Effects of Adrenocorticosteroids. Learn about glucocorticoids and mineralocorticoids, their roles in metabolism, immune response, and electrolyte balance. |
K |
Large group lecture |
MCQ & short answer questions |
| PHAR56.2 |
Apply Adrenocorticosteroid Therapy in Clinical Practice (Clinical Benefit). Appropriately prescribe and manage corticosteroid therapy for conditions like adrenal insufficiency, inflammation, and autoimmune diseases while minimizing side effects such as adrenal suppression and osteoporosis. |
K |
Large group lecture |
MCQ & short answer questions |
Practical
Pharmaceutical Dosage Forms
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR1.1 |
A. Understand the Types, Characteristics, and Functions of Pharmaceutical Dosage Forms.
B. Learn about various dosage forms (e.g., tablets, capsules, injections, topical formulations), their design, and how they affect drug absorption, distribution, and efficacy.
|
K/S/C |
Small groups lab |
MCQ |
| PHAR1.2 |
Apply Knowledge of Dosage Forms in Clinical Practice (Clinical Benefit). Select the appropriate dosage form based on patient needs, drug properties, and therapeutic goals, considering factors like patient compliance, onset of action, and side effects. |
K/S/C |
Small groups lab |
MCQ |
Routes of Drug Administration
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR2.1 |
A. Understand the Different Routes of Drug Administration and Their Characteristics.
B. Learn about the various routes of drug administration (e.g., oral, intravenous, intramuscular, subcutaneous, topical), their absorption mechanisms, advantages, and disadvantages.
|
K/S/C |
Small groups lab |
MCQ |
| PHAR2.2 |
Apply the Appropriate Route of Administration in Clinical Practice (Clinical Benefit). Select the most effective and appropriate route of drug administration based on the drug's properties, the patient's condition, and therapeutic goals to ensure optimal drug delivery and minimize adverse effects. |
K/S/C |
Small groups lab |
MCQ |
Calculation of Pharmacokinetic Parameters
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR3.1 |
A. Understand the Key Pharmacokinetic Parameters and Their Calculation.
B. Learn about the key pharmacokinetic parameters (e.g., half-life, clearance, volume of distribution, and bioavailability) and how to calculate them using drug concentration-time data.
|
K/S/C |
Small groups lab |
MCQ |
| PHAR3.2 |
Apply Pharmacokinetic Calculations in Clinical Practice (Clinical Benefit). Use pharmacokinetic parameters to optimize drug dosing, adjust for patient-specific factors (e.g., renal or hepatic impairment), and ensure therapeutic drug levels while minimizing toxicity. |
K/S/C |
Small groups lab |
MCQ |
Prescription-Order Writing
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR4.1 |
A. Understand the Components and Legal Requirements of a Prescription.
B. Learn about the essential components of a prescription (e.g., patient information, drug name, dosage, frequency, duration) and the legal requirements to ensure safe and accurate prescribing.
|
K/S/C |
Small groups lab |
MCQ |
| PHAR4.2 |
Apply Proper Prescription Writing in Clinical Practice (Clinical Benefit). Write clear, accurate prescriptions that follow legal and clinical guidelines, considering factors like drug interactions, patient conditions, and cost-effectiveness to ensure patient safety and optimal therapeutic outcomes. |
K/S/C |
Small groups lab |
MCQ |
Drug-Induced Discoloration of Urine
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR5.1 |
A. Understand the Mechanisms and Causes of Drug-Induced Urine Discoloration.
B. Learn about the various drugs (e.g., rifampin, phenazopyridine, levodopa) that can cause changes in urine color, and understand the underlying pharmacological mechanisms behind these effects.
|
K/S/C |
Small groups lab |
MCQ |
| PHAR5.2 |
Identify and Manage Drug-Induced Urine Discoloration in Clinical Practice (Clinical Benefit). Recognize the clinical significance of drug-induced urine discoloration, differentiate it from pathological causes, and provide patient education to alleviate concerns while managing the underlying condition or adjusting treatment if necessary. |
K/S/C |
Small groups lab |
MCQ |
Drug Discovery and Development; Toxicity Evaluation and Clinical Trials
| Number |
Learning Objective |
Domain K/S/A/C |
Teaching Learning Methods |
Assessment Methods |
| PHAR6.1 |
Understand the Drug Discovery and Development Process. Learn the stages of drug discovery and development, from preclinical research, lead compound identification, and optimization, to clinical trials and regulatory approval. |
K/S/C |
Small groups lab |
MCQ |
| PHAR6.2 |
Apply Knowledge of Toxicity Evaluation and Clinical Trials in Drug Development (Clinical Benefit). Understand the importance of toxicity evaluation and preclinical studies to ensure drug safety, and learn how clinical trials are designed and conducted to assess drug efficacy and safety, ultimately benefiting patient care and regulatory compliance. |
K/S/C |
Small groups lab |
MCQ |
